{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:28:18Z","timestamp":1780104498952,"version":"3.54.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-026-06106-3","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T06:42:59Z","timestamp":1774334579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tapering strategies for immunosuppressive, corticosteroid, and biologic therapy in lupus nephritis: a national survey of rheumatology and nephrology practices in Saudi Arabia"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3201-1308","authenticated-orcid":false,"given":"Roaa","family":"Aljohani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8495-9064","authenticated-orcid":false,"given":"Fahidah","family":"Alenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8106-8602","authenticated-orcid":false,"given":"Alaa","family":"Alem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawaher","family":"Aljabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0904-0514","authenticated-orcid":false,"given":"Samar","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"6106_CR1","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1177\/09612033251360628","volume":"34","author":"R Aljohani","year":"2025","unstructured":"Aljohani R, Alenzi F, Aboabat A et al (2025) Disease characteristics and outcomes of lupus nephritis in Saudi Arabia: A systematic review. Lupus 34:1184\u20131198. https:\/\/doi.org\/10.1177\/09612033251360628","journal-title":"Lupus"},{"key":"6106_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/acr.20683","volume":"64","author":"RW Jakes","year":"2012","unstructured":"Jakes RW, Bae S, Louthrenoo W et al (2012) Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: Prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken) 64:159\u2013168. https:\/\/doi.org\/10.1002\/acr.20683","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"6106_CR3","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s00296-022-05183-4","volume":"42","author":"F Fatoye","year":"2022","unstructured":"Fatoye F, Gebrye T, Mbada C (2022) Global and regional prevalence and incidence of systemic lupus erythematosus in low-and-middle income countries: a systematic review and meta-analysis. Rheumatol Int 42:2097\u20132107. https:\/\/doi.org\/10.1007\/s00296-022-05183-4","journal-title":"Rheumatol Int"},{"key":"6106_CR4","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1177\/0961203308100660","volume":"18","author":"A Al Arfaj","year":"2009","unstructured":"Al Arfaj A, Khalil N (2009) Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia. Lupus 18:465\u2013473. https:\/\/doi.org\/10.1177\/0961203308100660","journal-title":"Lupus"},{"key":"6106_CR5","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.3390\/jcm13082211","volume":"13","author":"F Alenzi","year":"2024","unstructured":"Alenzi F, Ateka-Barrutia O, Ken Cheah C et al (2024) Lupus Nephritis Outcomes after Stopping Immunosuppression. J Clin Med 13:2211. https:\/\/doi.org\/10.3390\/jcm13082211","journal-title":"J Clin Med"},{"key":"6106_CR6","first-page":"S75","volume":"31","author":"G Moroni","year":"2013","unstructured":"Moroni G, Longhi S, Giglio E et al (2013) What happens after complete withdrawal of therapy in patients with lupus nephritis. Clin Exp Rheumatol 31:S75\u201381","journal-title":"Clin Exp Rheumatol"},{"key":"6106_CR7","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/ndt\/gfk073","volume":"21","author":"G Moroni","year":"2006","unstructured":"Moroni G, Gallelli B, Quaglini S et al (2006) Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dialysis Transplantation 21:1541\u20131548. https:\/\/doi.org\/10.1093\/ndt\/gfk073","journal-title":"Nephrol Dialysis Transplantation"},{"key":"6106_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3904\/kjim.2023.255","volume":"39","author":"H Jeon","year":"2024","unstructured":"Jeon H, Lee J, Moon S-J et al (2024) Predictors of renal relapse in Koreans with lupus nephritis after achieving complete response: a 35-years of experience at a single center. Korean J Intern Med 39:347\u2013359. https:\/\/doi.org\/10.3904\/kjim.2023.255","journal-title":"Korean J Intern Med"},{"key":"6106_CR9","doi-asserted-by":"publisher","unstructured":"Fanouriakis A, Kostopoulou M, Anders H-J et al (2025) EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update. https:\/\/doi.org\/10.1016\/j.ard.2025.09.007. Ann Rheum Dis","DOI":"10.1016\/j.ard.2025.09.007"},{"key":"6106_CR10","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","volume":"105","author":"BH Rovin","year":"2024","unstructured":"Rovin BH, Ayoub IM, Chan TM et al (2024) KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int 105:S1\u2013S69. https:\/\/doi.org\/10.1016\/j.kint.2023.09.002","journal-title":"Kidney Int"},{"key":"6106_CR11","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1002\/art.43212","volume":"77","author":"LR Sammaritano","year":"2025","unstructured":"Sammaritano LR, Askanase A, Bermas BL et al (2025) 2024 American College of Rheumatology (<\u2009scp>ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol 77:1115\u20131135. https:\/\/doi.org\/10.1002\/art.43212","journal-title":"Arthritis Rheumatol"},{"key":"6106_CR12","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1136\/annrheumdis-2022-222435","volume":"81","author":"N Jourde-Chiche","year":"2022","unstructured":"Jourde-Chiche N, Costedoat-Chalumeau N, Baumstarck K et al (2022) Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial. Ann Rheum Dis 81:1420\u20131427. https:\/\/doi.org\/10.1136\/annrheumdis-2022-222435","journal-title":"Ann Rheum Dis"},{"key":"6106_CR13","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.ekir.2023.05.012","volume":"8","author":"N Jourde-Chiche","year":"2023","unstructured":"Jourde-Chiche N, Bobot M, Burtey S et al (2023) Weaning Maintenance Therapy in Lupus Nephritis: For Whom, When, and How? Kidney Int Rep 8:1481\u20131488. https:\/\/doi.org\/10.1016\/j.ekir.2023.05.012","journal-title":"Kidney Int Rep"},{"key":"6106_CR14","doi-asserted-by":"publisher","first-page":"576","DOI":"10.4103\/sjkdt.sjkdt_215_23","volume":"34","author":"A AlMutairi","year":"2023","unstructured":"AlMutairi A, Al-Mayouf SM, Kari J et al (2023) Practice Patterns and Approach to Childhood Lupus Nephritis in Saudi Arabia. Saudi J Kidney Dis Transpl 34:576\u2013591. https:\/\/doi.org\/10.4103\/sjkdt.sjkdt_215_23","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"6106_CR15","doi-asserted-by":"publisher","unstructured":"Ibrahim ST, Edwards CJ, Ehrenstein MR et al (2023) Differences in management approaches for lupus nephritis within the UK. Rheumatol Adv Pract 8. https:\/\/doi.org\/10.1093\/rap\/rkae017","DOI":"10.1093\/rap\/rkae017"},{"key":"6106_CR16","doi-asserted-by":"publisher","unstructured":"Zimba O, Gasparyan AY (2023) Designing, Conducting, and Reporting Survey Studies: A Primer for Researchers. J Korean Med Sci 38. https:\/\/doi.org\/10.3346\/jkms.2023.38.e403","DOI":"10.3346\/jkms.2023.38.e403"},{"key":"6106_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J et al (2024) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83:15\u201329. https:\/\/doi.org\/10.1136\/ard-2023-224762","journal-title":"Ann Rheum Dis"},{"key":"6106_CR18","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/rheumatology\/keae381","volume":"64","author":"A Panagiotopoulos","year":"2025","unstructured":"Panagiotopoulos A, Kapsia E, El Michelakis I et al (2025) Immunosuppressives discontinuation after renal response in lupus nephritis: predictors of flares, time to withdrawal and long-term outcomes. Rheumatology 64:1894\u20131903. https:\/\/doi.org\/10.1093\/rheumatology\/keae381","journal-title":"Rheumatology"},{"key":"6106_CR19","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1136\/ard-2023-224919","volume":"83","author":"S Pitsigavdaki","year":"2024","unstructured":"Pitsigavdaki S, Nikoloudaki M, Garantziotis P et al (2024) Pragmatic targets for moderate\/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression. Ann Rheum Dis 83:464\u2013474. https:\/\/doi.org\/10.1136\/ard-2023-224919","journal-title":"Ann Rheum Dis"},{"key":"6106_CR20","doi-asserted-by":"publisher","first-page":"e584","DOI":"10.1016\/S2665-9913(23)00209-6","volume":"5","author":"J Cho","year":"2023","unstructured":"Cho J, Shen L, Huq M et al (2023) Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study. Lancet Rheumatol 5:e584\u2013e593. https:\/\/doi.org\/10.1016\/S2665-9913(23)00209-6","journal-title":"Lancet Rheumatol"},{"key":"6106_CR21","doi-asserted-by":"publisher","first-page":"e001375","DOI":"10.1136\/lupus-2024-001375","volume":"12","author":"P Vidal-Montal","year":"2025","unstructured":"Vidal-Montal P, Narv\u00e1ez J, Fulladosa X et al (2025) Outcomes following immunosuppressive therapy withdrawal after complete renal response in proliferative lupus nephritis. Lupus Sci Med 12:e001375. https:\/\/doi.org\/10.1136\/lupus-2024-001375","journal-title":"Lupus Sci Med"},{"key":"6106_CR22","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.kint.2019.07.018","volume":"97","author":"A Malvar","year":"2020","unstructured":"Malvar A, Alberton V, Lococo B et al (2020) Kidney biopsy\u2013based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis. Kidney Int 97:156\u2013162. https:\/\/doi.org\/10.1016\/j.kint.2019.07.018","journal-title":"Kidney Int"},{"key":"6106_CR23","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.kint.2018.05.021","volume":"94","author":"M De Rosa","year":"2018","unstructured":"De Rosa M, Azzato F, Toblli JE et al (2018) A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int 94:788\u2013794. https:\/\/doi.org\/10.1016\/j.kint.2018.05.021","journal-title":"Kidney Int"},{"key":"6106_CR24","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/ndt\/gfv296","volume":"32","author":"A Malvar","year":"2017","unstructured":"Malvar A, Pirruccio P, Alberton V et al (2017) Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dialysis Transplantation 32:1338\u20131344. https:\/\/doi.org\/10.1093\/ndt\/gfv296","journal-title":"Nephrol Dialysis Transplantation"},{"key":"6106_CR25","doi-asserted-by":"publisher","first-page":"5014","DOI":"10.1093\/rheumatology\/keaf243","volume":"64","author":"K Ohmura","year":"2025","unstructured":"Ohmura K, Shimizu H, Tanaka Y et al (2025) Impact of glucocorticoid tapering speed on renal outcomes in proliferative lupus nephritis: a multicentre retrospective study. Rheumatology 64:5014\u20135022. https:\/\/doi.org\/10.1093\/rheumatology\/keaf243","journal-title":"Rheumatology"},{"key":"6106_CR26","doi-asserted-by":"publisher","first-page":"e005877","DOI":"10.1136\/rmdopen-2025-005877","volume":"11","author":"IE Michelakis","year":"2025","unstructured":"Michelakis IE, Panagiotopoulos A, Kapsia E et al (2025) Predictors of a successful glucocorticoid tapering and withdrawal in an inception cohort of patients with lupus nephritis and associations with long-term outcomes and damage accrual. RMD Open 11:e005877. https:\/\/doi.org\/10.1136\/rmdopen-2025-005877","journal-title":"RMD Open"},{"key":"6106_CR27","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1177\/09612033251352709","volume":"34","author":"SG Kandinata","year":"2025","unstructured":"Kandinata SG, Awalia, Yuliasih et al (2025) Immunosuppressive therapy withdrawal in lupus nephritis, is it possible? A systematic review. Lupus 34:1003\u20131012. https:\/\/doi.org\/10.1177\/09612033251352709","journal-title":"Lupus"},{"key":"6106_CR28","doi-asserted-by":"publisher","first-page":"e000538","DOI":"10.1136\/lupus-2021-000538","volume":"8","author":"RF van Vollenhoven","year":"2021","unstructured":"van Vollenhoven RF, Bertsias G, Doria A et al (2021) 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med 8:e000538. https:\/\/doi.org\/10.1136\/lupus-2021-000538","journal-title":"Lupus Sci Med"},{"key":"6106_CR29","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1056\/NEJM197205252862116","volume":"286","author":"RG Aptekar","year":"1972","unstructured":"Aptekar RG JLDADS (1972) Exacerbation of SLE Nephritis after Cyclophosphamide Withdrawal. N Engl J Med 286:1159\u20131160. https:\/\/doi.org\/10.1056\/NEJM197205252862116","journal-title":"N Engl J Med"},{"key":"6106_CR30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJM197301182880303","volume":"288","author":"E Sharon","year":"1973","unstructured":"Sharon E, Kaplan D, Diamond HS (1973) Exacerbation of Systemic Lupus Erythematosus after Withdrawal of Azathioprine Therapy. N Engl J Med 288:122\u2013124. https:\/\/doi.org\/10.1056\/NEJM197301182880303","journal-title":"N Engl J Med"},{"key":"6106_CR31","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1136\/annrheumdis-2020-217485","volume":"79","author":"E van Mulligen","year":"2020","unstructured":"van Mulligen E, Weel AE, Hazes JM et al (2020) Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial. Ann Rheum Dis 79:1174\u20131181. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217485","journal-title":"Ann Rheum Dis"},{"key":"6106_CR32","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1136\/annrheumdis-2018-214970","volume":"78","author":"E van Mulligen","year":"2019","unstructured":"van Mulligen E, de Jong PHP, Kuijper TM et al (2019) Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study. Ann Rheum Dis 78:746\u2013753. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214970","journal-title":"Ann Rheum Dis"},{"key":"6106_CR33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/annrheumdis-2014-206439","volume":"75","author":"J Haschka","year":"2016","unstructured":"Haschka J, Englbrecht M, Hueber AJ et al (2016) Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis 75:45\u201351. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206439","journal-title":"Ann Rheum Dis"},{"key":"6106_CR34","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1093\/rheumatology\/keab373","volume":"61","author":"M Zen","year":"2022","unstructured":"Zen M, Fuzzi E, Loredo Martinez M et al (2022) Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis. Rheumatology 61:688\u2013695. https:\/\/doi.org\/10.1093\/rheumatology\/keab373","journal-title":"Rheumatology"}],"updated-by":[{"DOI":"10.1007\/s00296-026-06120-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000}}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06106-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06106-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06106-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T03:45:32Z","timestamp":1779767132000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-026-06106-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6106"],"URL":"https:\/\/doi.org\/10.1007\/s00296-026-06106-3","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due spelling error in author name Alaa Alem. Now, it has been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00296-026-06120-5","URL":"https:\/\/doi.org\/10.1007\/s00296-026-06120-5","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was obtained from the Research Ethics Committee (CM-REC), College of Medicine, Taibah University, Medina, Saudi Arabia (Study ID: TU-25-044; IRB No. IRB00010413; approval date: 15 May 2025).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"An artificial intelligence\u2013assisted language tool (ChatGPT, OpenAI) was used solely for language editing and stylistic refinement. All scientific content, analyses, and interpretations were performed and verified by the authors, who take full responsibility for the integrity of the work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of artificial intelligence"}}],"article-number":"65"}}